YOKKAICHI, Japan & IRVINE, Calif. - Saturday, July 16th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) and Western Digital Corporation (NASDAQ:WDC) today celebrated the opening of the New Fab 2 semiconductor fabrication facility located in Yokkaichi, Mie Prefecture, Japan.
Expanded use of flash memory in smartphones, SSDs, and other applications is driving continued growth of the global flash memory market. The New Fab 2 facility will support the conversion of the companies’ 2D NAND capacity to 3D flash memory, allowing realization of solutions offering higher densities and better device performance.
Construction of New Fab 2 began in September 2014. Following partial completion of the facility in October 2015, Toshiba and SanDisk (acquired in May 2016 by Western Digital Technologies Inc., a wholly owned subsidiary of Western Digital Corporation) worked together to implement leading-edge manufacturing capabilities for mass pro
...
Read more »
|
Toronto, Canada - Sunday, July 17th 2016 [ME NewsWire]
In recognition of its outstanding solutions and services in the public sector, ITWORX Education has been named as Microsoft Partner of the Year award finalist, at the 2016 Microsoft Worldwide Partner Conference (WPC), in Toronto, Canada.
Having achieved excellence in the ‘Public Sector: CityNext’ category, based on its WinjiGo Syrian Refugees project; an innovative and holistic e-learning solution for underserved and underprivileged Syrian refugee children. The prestigious title reaffirms ITWORX Education’s status as a forerunner in non-traditional educational initiatives, in the framework of its overarching mission and vision at the service of knowledge-based economies in largely underserved areas around the world.
In his remarks on the company’s distinct achievement, Mr. Hatem Sallam, CEO of ITWORX Education, said:
“At ITWORX Education, we are honored to be named as a Final
...
Read more »
|
INCHEON, Korea - Monday, July 18th 2016 [ME NewsWire]
If approved, SB5, a biosimilar candidate referencing Humira® (adalimumab), will be Samsung Bioepis’ third anti-TNF-α biosimilar in Europe
The Marketing Authorization Application for SB5 was based on a 52-week Phase III study which showed SB5’s comparable efficacy and safety to Humira® among different treatment groups, including those who switched from Humira® to SB5
(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB5, a biosimilar candidate referencing Humira® (adalimumab).
SB5 is Samsung Bioepis’ third anti-TNF-α biosimilar candidate submitted for review to the EMA, following Benepali® (etanercept) and Flixabi® (infliximab), both of which have since received European C
...
Read more »
| |